Imagine you are sitting down with a dear friend that you haven’t seen in years because he ran away from an unloving, unsupportive home, from a town where he was different, picked on, and knew he could never be safe - at least that is how he felt, - to a place where he would find love, and the supportive family he so dearly wanted. He discloses that he is gay and living with HIV infection. He says not to worry, that it’s ok, and then he says, “There’s more.” You feel your heart beat faster and time suspends.
Technology is great…when it works. This phrase comes to mind every time technology is supposed to enhance an experience and a malfunction causes that experience to cease. We know that technology should have the capacity to transform our lives, including our lives as HIV care providers. But in order for it to do so, it has to work. It has to be usable (i.e. easy, reliable, and fast). While iPad Minis have been on the market for several years now, a review of the literature yielded no current studies to examine their usability or effectiveness in clinical use.
Quite often when you think about the U.S. Virgin Islands (USVI), you envision a beautiful vacation on the beach drinking Pina Coladas, eating local food and listening to the sounds of island music. Although the Virgin Islands are truly paradise vacation spots, they are not free from the impact of HIV/AIDS. The three islands of St. Croix, St. Thomas, and St. John are unique and face their own challenges with testing, diagnosis, and treatment.
It’s that time of the year again: open enrollment season within the Health Insurance Marketplace!
Ryan White HIV/AIDS Program grantees are actively engaged in Affordable Care Act (ACA) activities, connecting patients with health insurance—many for the first time in their lives. The transformative power of health insurance cannot be overstated, particularly for individuals with a chronic disease like HIV and whom often times suffer from a myriad of other health conditions.
New data show that etravirine (ETR) substantially lowers plasma concentrations of dolutegravir (DTG) (DTG Cmin decreased 88%, AUC decreased 71%). This effect is lessened by coadministration of ritonavir-boosted PIs: the combination of ETR + DTG + darunavir/ritonavir (600/100 mg BID) resulted in a decrease in DTG Cmin and AUC of 37% and 25%, respectively. When ETR + DTG were given with lopinavir/ritonavir, the DTG Cmin and AUC were increased slightly. No data are available for the interaction with atazanavir/ritonavir.
Bisphosphonates medications (Fosamax, Boniva, Alendronate) are commonly used in the treatment of bone diseases such as osteoporosis, Paget disease, and multiple myeloma, and to limit bone pain and hypercalcemia associated with malignant metastatic bone lesions.